

Vaccine Advisory Workgroup Meeting
Annotated Agenda
Monday, September 28, 2020

Location: Google Meet meet.google.com/vti-zaaa-gwg

Joining via phone: [1 910-939-8631](tel:19109398631); 816827198#

12:30-12:40	<p>Welcome</p> <ul style="list-style-type: none"> - Co-Chair of the Vaccine Advisory Workgroup: Kelly Goode, PharmD, BCPS, FAPhA, FCCP <i>Professor and Director, Community-Based Residency Program</i> <i>Virginia Commonwealth University School of Pharmacy</i> <i>President, Virginia Pharmacists Association</i> <i>Former President, American Pharmacists Association</i> - Introduction of new members
12:40-12:55	<p>Federal and State Updates Christy Gray, MSH, CHES, CHTS-CP <i>Director Division of Immunization Virginia Department of Health</i></p> <hr/> <p>Recent Meetings</p> <ul style="list-style-type: none"> - ACIP Meeting 9-22-2020 - National Vaccine Advisory Committee Meeting 9-23 and 9-24 2020 - National Governors Association/National Council of State Legislatures Meeting: State Leadership in Vaccine Policy Virtual Convening 9-25-2020 <hr/> <p>CDC Released Information Released 9-16-2020</p> <ul style="list-style-type: none"> - CDC “Playbook” Published - Reporting Data Elements Dictionary Published - COVID-19 Vaccine Provider Agreement and Profile Published - Operation Warp Speed published strategy (infographic to be shared in meeting) <hr/> <p>State Updates:</p> <ul style="list-style-type: none"> - Update on Influenza Campaign - State Vaccination Plan - Initial Draft State, Date Due to CDC 10-16-2020 - VDH COVID-19 Vaccine Provider Intent Form - VIIS Onboarding Guide - Population Group Estimates and Update of Current Data/Surveys - Planned tabletop exercise for October - Overview of a simplified listed of COVID-19 Vaccine Steps
12:55-1:05	<p>Vaccine Advisory Workgroup Structure Updates</p> <hr/> <p>Charter</p> <ul style="list-style-type: none"> - Expectations

	<ul style="list-style-type: none"> - Cadence of Meetings: every 3 weeks instead of every 2 weeks (allowing subgroups to meet in between) <p>Member Listing Tentative Timeline and Steps</p>
1:05-1:15	<p>Sub-workgroup Introduction and Meeting Times</p> <hr/> <p>Barriers to Vaccination Co-Chairs: Carolyn Moneymaker, MD (<i>Immunize Virginia</i>) Stuart Henochowicz, MD, MBA, FACP (<i>American College of Physicians</i>)</p> <ul style="list-style-type: none"> - Identify strategies, needs and obstacles for public and private providers in order to assist in administering COVID-19 vaccine. - Identify populations outside of CDC critical populations that need to be considered within Virginia. <hr/> <p>Safety and Efficacy Co-Chairs: Costi Sifri, MD, FACP FIDSA (<i>University of Virginia School of Medicine and University of Virginia Medical System</i>) Joshua Crawford, PharmD, BCPS (<i>Bon Secours Mercy Health</i>)</p> <ul style="list-style-type: none"> - Review data from COVID-19 trials provided through the Food and Drug Administration and Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) regarding the safety and efficacy of COVID-19 vaccine candidates. <hr/> <p>Partnerships Co-Chairs: Sean Connaughton (<i>Virginia Hospital & Healthcare Association</i>) April Payne, MBA, LNHA (<i>Virginia Center for Assisted Living. Quality Improvement</i>)</p> <ul style="list-style-type: none"> - Identify and help establish partnerships with trusted community organizations in order to facilitate communication channels, methods for rapidly disseminating information and ensuring that critical populations have access to the vaccination. - Establish points of contact (POCs) for specific organizations within the community who may serve as partner and trusted sources within the community and critical population groups. <hr/> <p>Communications and Messaging Co-Chairs: Gaylene Kanoyton (<i>Celebrate Healthcare</i>) Wendy Klein, MD, MACP (<i>Health Brigade</i>)</p> <ul style="list-style-type: none"> - Vet messaging of COVID-19 vaccine to the population, including identifying key audiences, effective communication activities, and messaging considerations such as risk/crisis response communication messaging and delivery.
1:15-1:25	Open Discussion (<i>if time allows</i>)
1:25-1:30	<p>Closing & Wrap-up</p> <ul style="list-style-type: none"> - Summarize action steps - Next meeting date: Tentatively planning for October 19, 2020